Iron metabolic disorder in chronic hepatitis C: Mechanisms and relevance to hepatocarcinogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue S4, 2013, Pages 93-98

  Hino, Keisuke ^a   Nishina, Sohji ^a   Hara, Yuichi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Hepatitis C; Hepcidin; Iron; Oxidative stress; Reactive oxygen species

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; HEPCIDIN; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSFERRIN;

ARTICLE; CHRONIC LIVER DISEASE; DISEASE COURSE; DISEASE SEVERITY; FENTON REACTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; IRON METABOLISM DISORDER; IRON OVERLOAD; IRON STORAGE; LIVER CARCINOGENESIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

HEPATITIS C; HEPCIDIN; IRON; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; IRON METABOLISM DISORDERS; LIVER; LIVER NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSCRIPTION, GENETIC; TRANSFERRIN;

EID: 84897625475     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12243     Document Type: Article

References (50)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
2. Tanaka H, Fujita N, Sugimoto R etal. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br. J. Cancer 2008; 98: 580-586.
3. Thursz M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut 2007; 56: 613-614.
4. Isomura T, Yano M, Hayashi H, Sakamoto N. Excess iron in the liver of patients with chronic hepatitis C. J. Clin. Electron. Microsc. 1992; 25: 231-237.
5. Fenton HJH. Oxidation of tartaric acid in presence of iron. J. Chem. Soc. 1894; 65: 899-910.
6. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991; 349: 431-434.
7. Fujita N, Horiike S, Sugimoto R etal. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic. Biol. Med. 2007; 42: 353-362.
8. Kato J, Kobune M, Nakamura T etal. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001; 61: 8697-8702.
9. Kato J, Miyanishi K, Kobune M etal. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007; 42: 830-836.
10. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117: 285-297.
11. Krause A, Neitz S, Magert HJ etal. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480: 147-150.
12. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001; 276: 7806-7810.
13. Pigeon C, Ilyin G, Courselaud B etal. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 2001; 276: 7811-7819.
14. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788.
15. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 2000; 275: 19906-19912.
16. McKie AT, Marciani P, Rolfs A etal. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 2000; 5: 299-309.
17. Donovan A, Brownlie A, Zhou Y etal. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
18. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
19. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 2005; 54: 980-986.
20. Bridle KR, Frazer DM, Wilkins SJ etal. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-673.
21. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest. 2005; 115: 2180-2186.
22. Babitt JL, Huang FW, Wrighting DM etal. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 2006; 38: 531-539.
23. Wang RH, Li C, Xu X etal. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005; 2: 399-409.
24. Pietrangelo A, Dierssen U, Valli L etal. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007; 132: 294-300.
25. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204-3209.
26. Courselaud B, Pigeon C, Inoue Y etal. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J. Biol. Chem. 2002; 277: 41163-41170.
27. Du X, She E, Gelbart T etal. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320: 1088-1092.
28. Rouault TA, Gordeuk V, Anderson G. The central role of the liver in iron strage and regulation of systemic iron homeostasis. In: Arias IM, Alter HJ, Boyer JL etal., ed. The Liver: Biology and Pathobiology, 5th edn. Hoboken, NJ: Wiley-Blackwell, 2009; 235-250.
29. Hofer H, Osterreicher C, Jessner W etal. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J. Hepatol. 2004; 40: 1018-1022.
30. Rulyak SJ, Eng SC, Patel K, McHutchison JG, Gordon SC, Kowdley KV. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am. J. Gastroenterol. 2005; 100: 332-337.
31. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-29.
32. Farinati F, Cardin R, De Maria N etal. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995; 22: 449-456.
33. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-768.
34. Brunt EM. Pathology of hepatic iron overload. Semin. Liver Dis. 2005; 25: 392-401.
35. Fiel MI, Schiano TD, Guido M etal. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am. J. Clin. Pathol. 2000; 113: 35-39.
36. Feder JN, Gnirke A, Thomas W etal. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996; 13: 399-408.
37. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003; 124: 1509-1523.
38. Fujita N, Sugimoto R, Takeo M etal. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med. 2007; 13: 97-104.
39. Girelli D, Pasino M, Goodnough JB etal. Reduced serum hepcidin levels in patients with chronic hepatitis C. J. Hepatol. 2009; 51: 845-852.
40. Korenaga M, Wang T, Li Y etal. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005; 280: 37481-37488.
41. Harrison-Findik DD, Schafer D, Klein E etal. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 2006; 281: 22974-22982.
42. Nishina S, Hino K, Korenaga M etal. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-238.
43. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 1420-1429.
44. Migita K, Abiru S, Maeda Y etal. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum. Immunol. 2006; 67: 27-32.
45. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J. Clin. Gastroenterol. 2005; 39: 71-74.
46. Bassett SE, Di Bisceglie AM, Bacon BR etal. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999; 29: 1884-1892.
47. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am. J. Gastroenterol. 2004; 99: 286-291.
48. Lambrecht RW, Sterling RK, Naishadham D etal. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140: 1490-500 e3.
49. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79-86.
50. Furutani T, Hino K, Okuda M etal. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-2098.